SCHEMBL4970822

SCHEMBL4970822

CCCCCCCC(=O)N(C)Cc1ccc(C)c(-c2ccc(CCC(=O)O)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
RARB P10826 3/20 0.46
KMT2A Q03164 1/20 0.43
FFAR1 O14842 3/20 0.42
FFAR4 Q5NUL3 2/20 0.42
LTB4R2 Q9NPC1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651537 0.85 ALDH1A1 (0.46) RARBKMT2ALTB4R2
SCHEMBL5651543 0.85 ALDH1A1 (0.46) RARBKMT2ALTB4R2
SCHEMBL4970598 0.83 AOC3 (0.53) KMT2AFFAR1FFAR4
SCHEMBL4968446 0.81 FFAR1 (0.48) RARBKMT2AFFAR1FFAR4
SCHEMBL5502668 0.80 AKR1C3 (0.46) FFAR1FFAR4LTB4R2
SCHEMBL5502667 0.80 AKR1C3 (0.46) FFAR1FFAR4LTB4R2
SCHEMBL68745 0.78 FFAR1 (0.42) RARBKMT2AFFAR1FFAR4
SCHEMBL4970260 0.77 THRA (0.42) FFAR1FFAR4LTB4R2
SCHEMBL5199653 0.77 KMT2A (0.47) KMT2AFFAR1FFAR4
SCHEMBL4970077 0.76 FAAH (0.46) RARBKMT2AFFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-06 US claimed
EP-1781274-B1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-11-05 EP disclosed
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-06 US disclosed
EP-1781274-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2007-05-09 EP disclosed
WO-2006018325-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD RARB 30/4885KMT2A 3074/4885FFAR1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.